New Technology– category –
-
CAR-T Cell Therapy Combined with Menin Inhibitors Achieves Over 90% Relapse-Free Survival in KMT2A-Rearranged Infant Leukemia
Cure Today USA Overview The combination of CAR-T cell therapy and menin inhibitors has demonstrated over 90% relapse-free survival in KMT2A-rearranged infant leukemia, a high-risk pediatric leukemia, significantly surpassing conventional... -
Meta-Analysis Integrates Safety and Efficacy of CAR T Therapy in Solid Malignancies, Lymphodepletion Enhances Response Rates
Frontiers Switzerland Overview A systematic review and meta-analysis evaluated the safety and efficacy of CAR T-cell therapy in solid malignancies, reporting an objective response rate (ORR) of 13% and a disease control rate (DCR) of 63%... -
Engineered Cord Blood CAR-NK Cells Achieve Clinical Responses in CD19+ B-Cell Malignancies with Minimized Severe Toxicity
National Academy of Engineering USA Overview Engineered cord blood-derived CAR-NK cells targeting CD19, incorporating IL-15 for enhanced proliferation and persistence, and an inducible Caspase-9 safety switch, have demonstrated clinical ... -
MIT and Johns Hopkins Develop 3D-Printed Handheld Microfluidic Device: Selectively Harvests Live Cells from Tissue for Early Cancer Detection and Personalized Therapy
3D Printing Industry USA Overview Researchers at MIT and Johns Hopkins University have developed a 3D-printed microfluidic handheld device capable of gently and selectively collecting live cells from freshly resected human tissue, while ... -
Functional 3D Bioprinted Kidney Organoids Demonstrate Metabolic Filtration, Advancing Organ Transplant Alternatives
Zuglu Education USA Overview Researchers have successfully 3D bioprinted functional kidney organoids using iPS cells, angiogenic bio-inks, and laser-assisted bioprinting. These organoids were shown to filter metabolic waste and reabsorb ... -
CAR T-cells: Alpha-2,3-Sialylation function explained via BioRxiv
bioRxiv Unknown Overview A new preprint on bioRxiv, titled "CAR T-cells and is induced by LIF and glucocorticoids," suggests that α2,3-sialylation plays a role in CAR T-cell functional modulation, with induction by LIF and glucocorticoid... -
Evotec: iPSC-derived CAR γδ T-cell manufacturing specs for 2026
News-Medical.Net Germany Overview Evotec has established a scalable, xeno-free bioprocess platform for developing immune-evasive and tumor microenvironment (TME)-resistant iPSC-derived CAR γδ T-cells (CAR iγδ T-cells) targeting hepatocel... -
Anito-cel: Phase 1 trial specs and 100% response rate for CAR-T
EurekAlert! (via Mass General Brigham) USA Overview In a Phase 1 clinical trial led by Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center, the BCMA-targeted CAR-T cell therapy, anitoc... -
UA Little Rock Secures Grant to Develop 3D Tissue Scaffold Replicating Human Intestinal Villi-Crypt Structures
University of Arkansas at Little Rock News USA Overview Dr. Sujan Ghosh at the University of Arkansas at Little Rock has received a grant to develop a novel 3D tissue scaffold capable of accurately mimicking the villi-crypt structures of... -
GC Cell’s CAR-NK Therapy GCC2005 Approved for Compassionate Use in Refractory T-Cell Lymphoma at SNUH, South Korea
Korea Biomedical Review South Korea Overview GC Cell's CAR-NK cell therapy, GCC2005, has received approval for compassionate use in patients with refractory T-cell lymphoma at Seoul National University Hospital (SNUH) in South Korea. Thi...
